Abstract: The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration, including as active ingredient thereof, an agonist of the central receptor of benzodiazepinics chosen among diazepam, lorazepam, bromazepam, triazolam, alprazolam, flunitrazepam, nitrazepam and midazolam maleate, in a mixture with a pharmaceutical excipient consisting of, at least, 70% of the weight of the final formulation containing 40-45% by weight of lactose, 15-27% by weight of sorbitol and 12-16% by weight of cellulose.

Abstract: The present invention refers to pharmaceutical compositions based on ketorolac or one of its salts pharmaceutically acceptable, as well as the use of ketorolac or one of its salts acceptable from pharmaceutical viewpoint, for preparation of a pharmaceutical composition (tablets) for sublingual administration, with the purpose of accelerating the pharmacological response to ketorolac, without making use of the injectable via. On the other hand, a pharmaceutical composition is described encompassing, as one of its active principles, ketorolac or one of its salts acceptable from pharmaceutical viewpoint, representing from 10 to 15% by weight, in relation to the total weight of the compound and as the essential excipient, a ternary mixture of lactose/sorbitol/cellulose, eventually in a mixture with other excipients acceptable from pharmaceutical viewpoint.

Abstract: Pharmaceutical compositions are for administered orally for treating patients affected by obesity. The compositions include orlistat (tetrahydrolipstatin) solubilized in pharmaceutically acceptable saturated hydrocarbons obtained from petroleum and one or more surfactants.

Abstract: The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration, including as active ingredient thereof, an agonist of the central receptor of benzodiazepinics chosen among diazepam, lorazepam, bromazepam, triazolam, alprazolam, flunitrazepam, nitrazepam and midazolam maleate, in a mixture with a pharmaceutical excipient consisting of, at least, 70% of the weight of the final formulation containing 40-45% by weight of lactose, 15-27% by weight of sorbitol and 12-16% by weight of cellulose.

Abstract: The present invention refers to pharmaceutical compositions based on ketorolac or one of its salts pharmaceutically acceptable, as well as the use of ketorolac or one of its salts acceptable from pharmaceutical viewpoint, for preparation of a pharmaceutical composition (tablets) for sublingual administration, with the purpose of accelerating the pharmacological response to ketorolac, without making use of the injectable via. On the other hand, a pharmaceutical composition is described encompassing, as one of its active principles, ketorolac or one of its salts acceptable from pharmaceutical viewpoint, representing from 10 to 15% by weight, in relation to the total weight of the compound and as the essential excipient, a ternary mixture of lactose/sorbitol/cellulose, eventually in a mixture with other excipients acceptable from pharmaceutical viewpoint.

Abstract: Crystalline non-hygroscopic salt of glutathione alkylester of the formula (I) ##STR1## wherein AA is an amino acid are disclosed.

Abstract: Inclusion complexes of dipyridamole with beta cyclodextrins in the molar ratio of dipyridamole to cyclodextrin ranging from 1:1 to 1:12 provides higher and more consistent blood concentrations than can be achieved by the dipyridamole alone.

Abstract: Acetylsalicylic acid thioesters having antipyretic activity and useful for the symptomatic treatment of influenza of formula: ##STR1## wherein n is zero or 1, R.sub.1 is hydrogen, methyl or carboxy and R.sub.2 is hydrogen or an acetamido group; a process for their preparation by reacting a functional derivative of acetylsalicylic acid with the suitable thiol; and pharmaceutical compositions containing them as active ingredient.

Abstract: The compound having formula (I) ##STR1## is obtained by reacting 1,2-diphenyl-4-[2-phenylsulfinyl)-ethyl]-4-hydroxymethyl-pyrazolidine-3,5- dione (hydroxymethylsulfinpyrazone) with nicotinic acid, in the presence of activating agents such as DCCD.(I) is endowed with marked vasodilating, antiaggregating and hypocholesterolemic properties.

Abstract: The present invention concerns novel phthalidyl esters of arylalkanoic acids having improved pharmacological properties in respect to the corresponding arylalkanoic acids having analgesic and anti-inflammatory activity, as well as pharmaceutical compositions containing them as active ingredients. The invention further relates to a method for improving the pharmacological properties of said arylalkanoic acids having analgesic and anti-inflammatory activity, by introducing, through an ester bond, a phthalidyl group.

Abstract: This invention relates to a derivative of 1-(p-chlorobenzoyl)-5-methoxy-2-methyl indole-3-acetic acid with 3-oxo-1-isobenzofuranyl, linked by an ester bond, more particularly to 1-(p-chlorobenzoyl)-5-methoxy-2-methyl indole-3-acet-3-oxo-1-isobenzofuranyl ester, as well as to its preparation and therapeutical use as an analgesic and anti-inflammatory agent.Said compound is prepared by reacting equi-molecular amounts of 1-(p-chlorobenzoyl)-5-methoxy-2-methyl indole-3-acetic acid and bromophthalide a few hours at room temperature, under a mild stirring, in the presence of a base.